Keyphrases
In Vivo Evaluation
100%
Ramipril
100%
Pediatric Drug Development
100%
Cyclodextrin
28%
Oral Liquid
28%
Acetic Acid
14%
Type 1 Diabetes Mellitus (T1DM)
14%
Systematic Optimization
14%
Hypertension
14%
Long-term Stability
14%
Diabetic Nephropathy
14%
Formulation Parameters
14%
Formulation Optimization
14%
Development Approach
14%
Type I Diabetes
14%
Pediatric Population
14%
Heart Failure Treatment
14%
Liquid Formulation
14%
Formulation Development
14%
Fatality
14%
Hypertension Management
14%
Congestive Heart Failure
14%
Heart Attack
14%
In Vivo Absorption
14%
Xanthan Gum
14%
Pediatric Use
14%
Stability Condition
14%
Hydroxypropyl-β-cyclodextrin (HP-β-CD)
14%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Development
100%
Ramipril
100%
Cyclodextrin
42%
Diabetic Nephropathy
28%
Congestive Heart Failure
28%
Liquid Formulation
28%
Potassium Acetate
14%
Complexation
14%
Heart Infarction
14%
Insulin Dependent Diabetes Mellitus
14%
Fatality
14%
Xanthan Gum
14%